STX Stock Overview
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Shield Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.063 |
| 52 Week High | UK£0.37 |
| 52 Week Low | UK£0.055 |
| Beta | 1.18 |
| 1 Month Change | -3.08% |
| 3 Month Change | -25.88% |
| 1 Year Change | -82.62% |
| 3 Year Change | -96.10% |
| 5 Year Change | -81.74% |
| Change since IPO | -95.99% |
Recent News & Updates
Recent updates
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares
Dec 15Shareholder Returns
| STX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -3.8% | 0.4% | 1.8% |
| 1Y | -82.6% | 4.1% | -3.7% |
Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned 4.1% over the past year.
Return vs Market: STX underperformed the UK Market which returned -3.7% over the past year.
Price Volatility
| STX volatility | |
|---|---|
| STX Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: STX is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: STX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 15 | Greg Madison | https://www.shieldtherapeutics.com |
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company’s lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Shield Therapeutics plc Fundamentals Summary
| STX fundamental statistics | |
|---|---|
| Market Cap | UK£34.92m |
| Earnings (TTM) | -UK£23.83m |
| Revenue (TTM) | UK£3.07m |
11.4x
P/S Ratio-1.5x
P/E RatioIs STX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STX income statement (TTM) | |
|---|---|
| Revenue | UK£3.07m |
| Cost of Revenue | UK£1.45m |
| Gross Profit | UK£1.62m |
| Other Expenses | UK£25.45m |
| Earnings | -UK£23.83m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.043 |
| Gross Margin | 52.62% |
| Net Profit Margin | -776.64% |
| Debt/Equity Ratio | 0% |
How did STX perform over the long term?
See historical performance and comparison